OIA
VIR icon

Optimum Investment Advisors’s Vir Biotechnology VIR Stock Holding History

Optimum Investment Advisors’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-40
Closed -$2K – 902
2021
Q4 		$2K Buy
+40
New +$1.57K ﹤0.01% 789

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
APF
Alaska Permanent Fund Juneau, Alaska $1.51B AUM 22.23% 1-Year Est. Return

Optimum Investment Advisors's VIR Position: Q1 2022 in Review

Optimum Investment Advisors sold out of Vir Biotechnology (VIR) in Q1 2022, closing a stake of 40 shares — an estimated $2K sold.

Optimum Investment Advisors first reported a position in VIR in Q4 2021 and held it in 1 quarter. The position peaked at $2K in Q4 2021. 204 funds tracked by Wall St. Rank hold VIR as of Q1 2022.

  • Optimum Investment Advisors reported no remaining Vir Biotechnology position as of Q1 2022 after selling out during the quarter.
  • Optimum Investment Advisors sold 40 Vir Biotechnology shares in Q1 2022, an estimated $2K.
  • Optimum Investment Advisors first reported a position in Vir Biotechnology in Q4 2021 and held it in 1 quarter.
  • Optimum Investment Advisors's Vir Biotechnology position peaked at $2K in Q4 2021.
  • 204 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2022.

Based on Optimum Investment Advisors's 13F filing for Q1 2022, filed 8 Apr 2022.